"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 0 | 1 | 1 |
| 2014 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Flickinger JC, Singh J, Yarman Y, Carlson RD, Barton JR, Waldman SA, Snook AE. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C. Front Immunol. 2022; 13:855759.
-
Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016 Jul; 21(5):821-33.
-
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014 May 01; 20(9):2433-44.
-
Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61.
-
Snook AE. Could targeting T-helper cells aid the development of effective cancer vaccines? Immunotherapy. 2014; 6(9):959-61.
-
Cheng HH, Lin DW, Yu EY. Advanced clinical states in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):561-71.
-
Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother. 2012 May; 61(5):713-23.
-
Chambers CV. Cancer vaccines. Prim Care. 2011 Dec; 38(4):703-15, viii-ix.
-
Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm. 2011 Aug; 26(4):407-15.
-
Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45.